Routine TDM was most frequently used for classical agents (methotrexate, cyclosporin A), antifungals, and antibiotics, but substantial interest was reported for targeted therapies, including BCL-2 inhibitors, BCR-ABL tyrosine kinase inhibitors, FLT3 inhibitors, and Bruton tyrosine kinase inhibitors. While firmly established for classical agents and anti-infectives, clinicians express growing interest in extending TDM to targeted therapies. Optimizing turnaround times, expanding assay availability, and integrating pharmacokinetics-informed dosing into clinical trials may further clarify the role of TDM within precision medicine approaches in hematology.

P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027

Treatment prioritized AA with cyclosporine and eltrombopag. Subsequently, the LPL/WM was treated with rituximab monotherapy...Although AA is a diagnosis of exclusion, its coexistence with lymphoma is rare. This case highlights the diagnostic and therapeutic complexity of AA and LPL/WM overlap and suggests that prioritizing the treatment of AA may lead to better outcomes.

P4, N=25, Recruiting, Medical University of Vienna

P4, N=100, Recruiting, Oslo University Hospital HF | Not yet recruiting --> Recruiting

P4, N=27, Completed, Oslo University Hospital HF | Not yet recruiting --> Completed

PPI and machine learning identified key targets including matrix metallopeptidase 2 (MMP2), mechanistic target of rapamycin (MTOR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). Molecular docking demonstrated that pimecrolimus had good binding activity with all the above targets, with binding energies all lower than -5 kcal/mol. This study systematically demonstrates that pimecrolimus may interfere with OLP progression by synergistically regulating key targets such as MMP2 (acting on erosive OLP), MTOR (acting on erosive OLP), and ERBB2 (acting on non-erosive OLP), and inhibiting the activity of inflammatory pathways including PI3K-Akt, TNF, and NF-κB.

A 75-year-old man with mHSPC was treated with Apa and leuprorelin. Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.

P4, N=45, Recruiting, Murdoch Childrens Research Institute | Phase classification: P2 --> P4